Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD-801 in Advanced Hepatocellular Carcinoma
NCT06092112Phase 1Completed
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD-801 in hepatocellular carcinoma (HCC), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Objective Response Rate based on mRECIST up to 24 months. Started Oct 2023; status: completed.
02
Drugs
CD-801
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06092112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092112.